Glucagon-like peptide-1 (GLP-1) analogs have emerged as a compelling therapeutic target for managing metabolic conditions. These naturally occurring molecules are secreted by the gut in response to meal intake, stimulating insulin production and suppressing glucagon release. GLP-1 agents exhibit promising therapeutic efficacy in treating type 2 dia